{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:18Z","timestamp":1792979898589,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009576","name":"Nantong Municipal Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["MSZ2023016"],"award-info":[{"award-number":["MSZ2023016"]}],"id":[{"id":"10.13039\/501100009576","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11096-025-01869-4","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T05:49:08Z","timestamp":1737092948000},"page":"767-774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-world safety of maribavir: a retrospective study based on signal detection in the FDA adverse event reporting system"],"prefix":"10.1007","volume":"47","author":[{"given":"Qineng","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunlin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"1869_CR1","doi-asserted-by":"publisher","first-page":"e6095","DOI":"10.7717\/peerj.6095","volume":"6","author":"I Ptaszy\u0144ska-Sarosiek","year":"2019","unstructured":"Ptaszy\u0144ska-Sarosiek I, Dunaj J, Zajkowska A, et al. Post-mortem detection of six human herpesviruses (HSV-1, HSV-2, VZV, EBV, CMV, HHV-6) in trigeminal and facial nerve ganglia by PCR. PeerJ. 2019;6:e6095. https:\/\/doi.org\/10.7717\/peerj.6095.","journal-title":"PeerJ"},{"issue":"3","key":"1869_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jccase.2023.04.013","volume":"28","author":"J Mancuso","year":"2023","unstructured":"Mancuso J, Dalia T, Goyal A, et al. Cytomegalovirus infection in heart transplant patient presenting as appendicitis. J Cardiol Cases. 2023;28(3):113\u20135. https:\/\/doi.org\/10.1016\/j.jccase.2023.04.013.","journal-title":"J Cardiol Cases"},{"issue":"6","key":"1869_CR3","doi-asserted-by":"publisher","first-page":"e62422","DOI":"10.7759\/cureus.62422","volume":"16","author":"A Muhammad","year":"2024","unstructured":"Muhammad A, Khan RTY, Waqar T, et al. Cytomegalovirus-associated colitis as a cause of lower gastrointestinal bleeding in kidney transplant recipients: a single-centered study. Cureus. 2024;16(6):e62422. https:\/\/doi.org\/10.7759\/cureus.62422.","journal-title":"Cureus."},{"issue":"11","key":"1869_CR4","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.3390\/v15112227","volume":"15","author":"G Shapira","year":"2023","unstructured":"Shapira G, Volkov H, Fabian I, et al. Genomic markers associated with cytomegalovirus DNAemia in kidney transplant recipients. Viruses. 2023;15(11):2227. https:\/\/doi.org\/10.3390\/v15112227.","journal-title":"Viruses"},{"issue":"1","key":"1869_CR5","doi-asserted-by":"publisher","first-page":"e13696","DOI":"10.1111\/cts.13696","volume":"17","author":"K Sun","year":"2024","unstructured":"Sun K, Fournier M, Sundberg AK, et al. Maribavir: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1):e13696. https:\/\/doi.org\/10.1111\/cts.13696.","journal-title":"Clin Transl Sci"},{"key":"1869_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","volume":"163","author":"J Piret","year":"2019","unstructured":"Piret J, Boivin G. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. Antivir Res. 2019;163:91\u2013105. https:\/\/doi.org\/10.1016\/j.antiviral.2019.01.011.","journal-title":"Antivir Res"},{"issue":"16","key":"1869_CR7","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/cells13161338","volume":"13","author":"M Marschall","year":"2024","unstructured":"Marschall M, Sch\u00fctz M, Wild M, et al. Understanding the cytomegalovirus cyclin-dependent kinase ortholog pUL97 as a multifaceted regulator and an antiviral drug target. Cells. 2024;13(16):1338. https:\/\/doi.org\/10.3390\/cells13161338.","journal-title":"Cells"},{"issue":"9","key":"1869_CR8","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1128\/JVI.00192-14","volume":"88","author":"R Webel","year":"2014","unstructured":"Webel R, Hakki M, Prichard MN, et al. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility. J Virol. 2014;88(9):4776\u201385. https:\/\/doi.org\/10.1128\/JVI.00192-14.","journal-title":"J Virol"},{"issue":"5","key":"1869_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/10600280221118959","volume":"57","author":"HL Kleiboeker","year":"2023","unstructured":"Kleiboeker HL, Descourouez JL, Schulz LT, et al. Maribavir for the management of cytomegalovirus in adult transplant recipients: a review of the literature and practical considerations. Ann Pharmacother. 2023;57(5):597\u2013608. https:\/\/doi.org\/10.1177\/10600280221118959.","journal-title":"Ann Pharmacother"},{"issue":"8","key":"1869_CR10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/cid\/ciy706","volume":"68","author":"GA Papanicolaou","year":"2019","unstructured":"Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis. 2019;68(8):1255\u201364. https:\/\/doi.org\/10.1093\/cid\/ciy706.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1869_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40506-021-00253-w","volume":"13","author":"N Jakharia","year":"2021","unstructured":"Jakharia N, Howard D, Riedel DJ. CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies. Curr Treat Options Infect Dis. 2021;13(3):123\u201340. https:\/\/doi.org\/10.1007\/s40506-021-00253-w.","journal-title":"Curr Treat Options Infect Dis"},{"issue":"12","key":"1869_CR12","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","volume":"381","author":"J Maertens","year":"2019","unstructured":"Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019;381(12):1136\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1714656.","journal-title":"N Engl J Med"},{"issue":"8","key":"1869_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.medmal.2018.03.006","volume":"48","author":"P Frange","year":"2018","unstructured":"Frange P, Leruez-Ville M. Maribavir, brincidofovir and letermovir: efficacy and safety of new antiviral drugs for treating cytomegalovirus infections. Med Mal Infect. 2018;48(8):495\u2013502. https:\/\/doi.org\/10.1016\/j.medmal.2018.03.006.","journal-title":"Med Mal Infect"},{"issue":"2","key":"1869_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","volume":"9","author":"RJ Yu","year":"2021","unstructured":"Yu RJ, Krantz MS, Phillips EJ, et al. Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS). J Allergy Clin Immunol Pract. 2021;9(2):819-29.e2. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.021.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"1869_CR15","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s11096-024-01784-0","volume":"46","author":"D Zou","year":"2024","unstructured":"Zou D, Hu Q, Liu Y, et al. Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database. Int J Clin Pharm. 2024;46(6):1419\u201326. https:\/\/doi.org\/10.1007\/s11096-024-01784-0.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"1869_CR16","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s11096-024-01778-y","volume":"46","author":"W Li","year":"2024","unstructured":"Li W, Yu Y, Li M, et al. Identification of novel signal of proton pump inhibitor-associated drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis. Int J Clin Pharm. 2024;46(6):1381\u201390. https:\/\/doi.org\/10.1007\/s11096-024-01778-y.","journal-title":"Int J Clin Pharm"},{"issue":"7","key":"1869_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"key":"1869_CR18","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","volume":"15","author":"F Zou","year":"2024","unstructured":"Zou F, Cui Z, Lou S, et al. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol. 2024;15:1338902. https:\/\/doi.org\/10.3389\/fphar.2024.1338902.","journal-title":"Front Pharmacol"},{"issue":"Suppl 3","key":"1869_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ajt.12006","volume":"13","author":"CN Kotton","year":"2013","unstructured":"Kotton CN. CMV: Prevention, Diagnosis and Therapy. Am J Transplant. 2013;13(Suppl 3):24\u201340. https:\/\/doi.org\/10.1111\/ajt.12006.","journal-title":"Am J Transplant"},{"issue":"3","key":"1869_CR20","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/ndt\/15.3.442","volume":"15","author":"Y Le Meur","year":"2000","unstructured":"Le Meur Y, Mons S, Moesch C, et al. The renal safety of high doses of valacyclovir for prevention of cytomegalovirus infection after renal transplantation. Nephrol Dial Transplant. 2000;15(3):442. https:\/\/doi.org\/10.1093\/ndt\/15.3.442.","journal-title":"Nephrol Dial Transplant"},{"key":"1869_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jcv.2015.12.012","volume":"75","author":"D Stachel","year":"2016","unstructured":"Stachel D, Stevens-Ayers T, Boeckh M. In vitro studies of the impact of maribavir on CMV-specific cellular immune responses. J Clin Virol. 2016;75:53\u20139. https:\/\/doi.org\/10.1016\/j.jcv.2015.12.012.","journal-title":"J Clin Virol"},{"issue":"3","key":"1869_CR22","doi-asserted-by":"publisher","first-page":"e14017","DOI":"10.1111\/tid.14017","volume":"25","author":"A Koff","year":"2023","unstructured":"Koff A, Narsana N, Alnimri M. Maribavir use in patients with renal impairment. Transpl Infect Dis. 2023;25(3):e14017. https:\/\/doi.org\/10.1111\/tid.14017.","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"1869_CR23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/infdis\/jiad293","volume":"229","author":"S Chou","year":"2024","unstructured":"Chou S, Alain S, Cervera C, et al. Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients. J Infect Dis. 2024;229(2):413\u201321. https:\/\/doi.org\/10.1093\/infdis\/jiad293.","journal-title":"J Infect Dis"},{"issue":"11","key":"1869_CR24","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","volume":"111","author":"DJ Winston","year":"2008","unstructured":"Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111(11):5403\u201310. https:\/\/doi.org\/10.1182\/blood-2007-11-121558.","journal-title":"Blood"},{"issue":"4","key":"1869_CR25","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","volume":"75","author":"RK Avery","year":"2022","unstructured":"Avery RK, Alain S, Alexander BD, et al. maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2022;75(4):690\u2013701. https:\/\/doi.org\/10.1093\/cid\/ciab988.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1869_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40265-022-01677-4","volume":"82","author":"C Kang","year":"2022","unstructured":"Kang C. Maribavir: first approval. Drugs. 2022;82(3):335\u201340. https:\/\/doi.org\/10.1007\/s40265-022-01677-4.","journal-title":"Drugs"},{"key":"1869_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/TCRM.S303052","volume":"18","author":"RG Gandhi","year":"2022","unstructured":"Gandhi RG, Kotton CN. Evaluating the safety of maribavir for the treatment of cytomegalovirus. Ther Clin Risk Manag. 2022;18:223\u201332. https:\/\/doi.org\/10.2147\/TCRM.S303052.","journal-title":"Ther Clin Risk Manag"},{"key":"1869_CR28","doi-asserted-by":"publisher","first-page":"1500810","DOI":"10.3389\/fphar.2024.1500810","volume":"15","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Yao Y, Zhu L. Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system. Front Pharmacol. 2024;15:1500810. https:\/\/doi.org\/10.3389\/fphar.2024.1500810.","journal-title":"Front Pharmacol"},{"issue":"10","key":"1869_CR29","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/14740338.2023.2223956","volume":"22","author":"DC Xiang","year":"2023","unstructured":"Xiang DC, Chen W, Fu ZW, et al. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Expert Opin Drug Saf. 2023;22(10):943\u201355. https:\/\/doi.org\/10.1080\/14740338.2023.2223956.","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"1869_CR30","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","volume":"12","author":"DJ Winston","year":"2012","unstructured":"Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012;12(11):3021\u201330. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04231.x.","journal-title":"Am J Transplant"},{"key":"1869_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fphar.2017.00367","volume":"8","author":"F Paech","year":"2017","unstructured":"Paech F, Bouitbir J, Kr\u00e4henb\u00fchl S. Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis. Front Pharmacol. 2017;8:367. https:\/\/doi.org\/10.3389\/fphar.2017.00367.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1869_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.therap.2022.10.002","volume":"78","author":"C Lacroix","year":"2023","unstructured":"Lacroix C, Maurier A, Largeau B, et al. Sex differences in adverse drug reactions: are women more impacted? Therapie. 2023;78(2):175\u201388. https:\/\/doi.org\/10.1016\/j.therap.2022.10.002.","journal-title":"Therapie"},{"key":"1869_CR33","doi-asserted-by":"publisher","first-page":"1420478","DOI":"10.3389\/fphar.2024.1420478","volume":"15","author":"J Lin","year":"2024","unstructured":"Lin J, Chen X, Luo M, et al. Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018\u20132023. Front Pharmacol. 2024;15:1420478. https:\/\/doi.org\/10.3389\/fphar.2024.1420478.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1869_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/pds.1323","volume":"16","author":"WP Stephenson","year":"2007","unstructured":"Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16(4):359\u201365. https:\/\/doi.org\/10.1002\/pds.1323.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01869-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01869-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01869-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T02:36:32Z","timestamp":1748572592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01869-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1869"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01869-4","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"22 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}